Denial management is no longer a back-office headache. It's a boardroom conversation. With claim denials climbing year over year and payers deploying their own AI to reject claims faster, healthcare organizations are under real pressure to adopt technology that can keep up.
But here's the problem. While denial rates keep rising, many health systems are stuck in 6-to-12 month vendor evaluation cycles. By the time a decision is made, the revenue already lost to preventable denials far outweighs whatever the new software will cost.
This guide is for the people making those decisions — CFOs, RCM directors, CIOs, and revenue cycle leaders — who need a practical framework for evaluating denial management software without losing half a year to the process.
Why Denial Management Technology Is a 2026 Priority
The data tells a clear story. Denial rates are accelerating, the cost of manual rework is unsustainable, and the organizations that have adopted AI-driven denial management are pulling ahead.
McKinsey's January 2026 research on agentic AI in revenue cycle management makes a strong case for starting with the back end — specifically denial management, AR follow-up, and underpayment resolution. These are labor-intensive, rules-governed tasks where staffing constraints are the primary bottleneck. That makes them ideal for AI automation.
Meanwhile, Deloitte's 2026 US Health Care Outlook found that over 80% of health care executives expect both agentic AI and generative AI to deliver moderate-to-significant value across back-office functions this year. Their survey also revealed a growing "AI divide" — early adopters expect cost savings above 20%, while those still watching from the sidelines expect far less.
Gartner's Market Guide for Revenue Cycle Management Software echoes this urgency, noting that most healthcare delivery organizations are still running on legacy solutions built for a different era. These systems hamper revenue efficiency and add to the technical debt CIOs already manage.
The message from every major research firm is consistent: denial management automation isn't a future initiative. It's a now initiative.
Who's Involved in the Evaluation — And What Each Role Cares About
One of the biggest reasons vendor evaluations drag on is that different stakeholders bring different priorities to the table. Understanding what each role actually needs from a denial management platform is the first step to keeping the process focused.
The CFO
Cares about net revenue impact, cost-to-collect reduction, and payback period. Wants clear projections based on the organization's own denial volume and payer mix — not industry averages. Needs confidence that the investment will show returns within a defined timeline.
The RCM Director
Lives in the day-to-day of denial rework. Wants to know: will this actually reduce the manual workload? Can it handle payer-specific denial patterns? Does it integrate into existing workflows without creating more work for an already stretched team?
The CIO / IT Leader
Worried about integration complexity, data security, and vendor reliability. Needs to know the solution works with their EHR (Epic, Cerner, MEDITECH), meets HIPAA/HITECH requirements, and won't create another maintenance headache for the IT team.
The CEO / Health System Leader
Evaluates vendor partnerships through a strategic lens. Looking for long-term viability, scalability across facilities, and alignment with the organization's broader technology and financial goals. Wants a partner, not just a product.
What the research says: KLAS Research's 2025 End-to-End Revenue Cycle Outsourcing report found that the highest-scoring technology partnerships are defined by deep governance, strong communication, and measurable improvements in collections and denial resolution. The report recommends engaging a broad team early — HR, IT, finance, and operations — to create realistic timelines and stronger internal buy-in.
The challenge isn't that these roles are involved. It's that without a structured evaluation framework, their competing priorities can stall the decision indefinitely. Accenture's Technology Vision 2025 identifies this tension directly: healthcare organizations need to balance trust strategy with technology strategy. Every stakeholder at the table needs to trust both the technology and the process for evaluating it.
How Most Organizations Evaluate Vendors Today (And Where Time Gets Lost)
Based on industry frameworks from Black Book Research, KLAS, and leading RCM consultancies, the typical evaluation follows a five-to-seven phase process. Here's what that usually looks like — and where the bottlenecks hide.
Internal Needs Assessment
Mapping current denial rates by category, quantifying cost-to-collect, and identifying the highest-impact pain points. This is where many organizations stall by trying to scope a full RCM overhaul instead of focusing on a single problem area like denial management.
Market Scan & Shortlisting
Identifying 5-10 vendors through KLAS reports, Black Book rankings, peer recommendations, G2/Capterra reviews, and industry conferences. Narrowing to 3-5 based on integration compatibility, specialty fit, and initial pricing alignment.
RFP, Demos & Evaluation Scoring
Issuing formal RFPs, scheduling demos, and scoring vendors against weighted criteria. This is the biggest time sink — coordinating schedules across a cross-functional committee of 8-12 people while vendors show every feature instead of focusing on what matters to your organization.
Reference Checks & Technical Due Diligence
Contacting client references (ideally similar in size and specialty), verifying EHR integration capabilities, reviewing security certifications (HITRUST, SOC 2), and running financial models on projected ROI.
Contract Negotiation & Pilot Planning
Final internal approvals, legal review, pricing negotiation, SLA definition, and implementation timeline. Adding a proof-of-concept or pilot phase here can extend the process another 30-60 days.
That's 6+ months before a single denial is touched. For a health system losing hundreds of thousands per month to unworked or unsuccessfully appealed denials, every week of delay carries a real cost.
The math of delay: Hospitals spend an estimated $19.7 billion annually managing denied claims (Experian Health, 2024). Meanwhile, as many as 60% of denied claims are never appealed — representing pure revenue loss (McKinsey, 2023). If your evaluation process takes 6 months longer than it needs to, multiply your monthly denial write-offs by six. That's the real cost of indecision.
A Faster, Smarter Evaluation Framework: 7 Steps
The goal isn't to skip due diligence. It's to cut the waste out of the process. Here's a practical framework used by forward-thinking health systems that have compressed vendor evaluation from 6+ months down to 8-12 weeks.
- Scope the problem narrowly. Don't evaluate an "end-to-end RCM transformation." Pick your highest-impact bottleneck — for most organizations, that's denial management at the back end of the revenue cycle. McKinsey's 2026 research specifically recommends this approach: start with one use case, prove it, then expand. A narrow scope shrinks your vendor shortlist and evaluation criteria immediately.
- Assemble a small, decision-empowered team. Four to five people maximum: one each from finance, RCM operations, IT, and clinical leadership. Designate a single decision-owner with final authority. KLAS recommends engaging this cross-functional team early, but "early" doesn't mean "large." Larger committees add noise, not better decisions.
- Define 5-7 outcome-based success metrics upfront. Skip the 50-feature comparison spreadsheet. Before you talk to a single vendor, agree on the metrics that matter: denial rate reduction, appeal success rate, time-to-resolution, cost-to-collect impact, clean claim rate, and integration timeline. Evaluate every vendor against these same metrics. Black Book Research's 18 KPIs framework is a useful starting point here.
- Demand use-case-specific demos, not product tours. Instead of watching a 90-minute product walkthrough, give your shortlisted vendors a specific scenario: "Show me how your system handles a CO-4 denial for timely filing on a Medicare Advantage claim." Payer-specific, denial-category-specific demonstrations reveal capability faster than any feature checklist.
- Run a 30-60 day proof-of-concept on your data. This is the single most important step. Ask your top 2 vendors to run a time-boxed pilot on a subset of your denial volume — a specific payer, denial category, or facility. Real results on your data beat vendor slide decks every time. McKinsey's guidance on evaluating AI pilots is clear: measure both near-term operational impact and what the results suggest about long-term financial value at scale.
- Evaluate vendors in parallel, not sequentially. Give your shortlisted vendors the same data set, the same timeline, and the same KPIs. Score them side by side. Sequential evaluations double your timeline for no benefit. Parallel evaluations create healthy competition and faster decisions.
- Set a hard 90-day decision deadline. Communicate the cost of delay in real dollars. Present the monthly revenue impact of unworked denials to your leadership team. Deadlines create focus. Open-ended evaluations create analysis paralysis.
What to Actually Look for in a Denial Management Platform
With the evaluation process defined, the next question is: what separates a good denial management platform from a great one? Based on guidance from Gartner, KLAS, and industry best practices, here's how to think about it.
| Evaluation Area | What to Ask |
|---|---|
| EHR Integration | Does it integrate natively with your EHR (Epic, Cerner, MEDITECH)? What's the implementation timeline? Is it HL7/FHIR compliant? 91% of RCM executives cite integration as a critical selection factor. |
| AI & Automation Depth | Is the AI doing real analytical work — pattern recognition, payer-specific denial categorization, automated appeal generation — or is it just a rules engine with an "AI" label? Gartner notes that GenAI, NLP, and RPA should all be present in modern RCM solutions. |
| Autonomous Capabilities | Can the system take action autonomously (e.g., generate and submit appeals) or does it just flag issues for human review? Deloitte's research shows 85% of health care leaders are investing in agentic AI that can execute tasks, not just recommend them. |
| Payer-Specific Intelligence | Does the platform track payer-specific policy changes, CARC/RARC patterns, and denial trends by payer? Generic denial rules don't work when each payer has different policies, timely filing windows, and appeal requirements. |
| Real-Time Analytics | Can you see denial trends, appeal success rates, and revenue impact in real-time dashboards? Can you generate reports on-demand without waiting for the vendor to compile them? |
| Security & Compliance | Is the vendor HIPAA compliant? Do they hold HITRUST or SOC 2 certifications? What's their data breach response protocol? Healthcare's average breach cost hit $9.77 million in 2024 — security is non-negotiable. |
| Proven Results | Can the vendor show case studies with measurable outcomes at organizations similar to yours? Black Book found 83% of organizations that implemented AI-driven automation saw at least 10% denial reduction within 6 months. |
| Pricing Transparency | Is pricing clear and predictable? Are there hidden onboarding fees, per-transaction charges, or long-term lock-in clauses? Understand total cost of ownership before signing. |
The Trust Question: How to Gain Confidence in AI-Powered Denial Management
For many healthcare leaders, the hardest part of this process isn't comparing features or running financial models. It's trusting that an AI system can handle something as complex and high-stakes as denial management.
This is a legitimate concern. Accenture's Technology Vision 2025 notes that healthcare executives overwhelmingly agree they need to build a trust strategy alongside their technology strategy. Deloitte's survey found that the primary adoption challenges for agentic AI are integrating with legacy systems and addressing risk and compliance — not the technology itself.
Here's how to build that trust methodically:
Start with a contained pilot, not a full deployment.
Pick a single denial category or payer and let the system work on a defined subset of claims. McKinsey recommends evaluating pilots on three dimensions: how it improves staff and patient experience, what the results suggest about long-term financial impact if scaled, and what near-term operational benefit it delivers. This gives you real evidence before committing to a broader rollout.
Require transparency in how the AI makes decisions.
Any denial management AI worth considering should be able to explain why it categorized a denial a certain way, why it chose a specific appeal strategy, and what data it used. If the vendor can't show you the reasoning behind the AI's decisions, that's a red flag.
Keep humans in the loop — strategically.
The best AI-powered denial management systems don't replace your team. They handle the high-volume, repetitive work autonomously and route complex exceptions to your experienced staff. McKinsey describes this as the natural next step for RCM: AI handles the rules-governed tasks at scale, humans manage the exceptions that require judgment. That's not a threat to your workforce — it's a force multiplier.
Measure outcomes against your own baseline.
Don't accept industry benchmarks as proof. Track the vendor's impact against your organization's own denial rates, appeal success rates, and time-to-resolution before and after deployment. If the technology works, the numbers will show it within 60-90 days.
Industry context: Deloitte's February 2026 survey found that 61% of healthcare organizations are already building or implementing agentic AI initiatives. Early adopters expect 20%+ cost savings within 2-3 years, while organizations still in "watching" mode expect significantly less. The gap between these two groups is widening — and it's increasingly tied to competitive positioning, not just cost efficiency.
Where DataRovers Fits In
At DataRovers, we focus on one thing: the back end of the revenue cycle where denials happen, revenue leaks, and teams burn out chasing claims they've already earned.
Our AI-powered Denials 360 platform is purpose-built for denial management — not bolted onto an EHR, not buried as a module inside a broader RCM suite. It covers the full denial lifecycle through a four-stage approach that moves denied claims from raw data to recovered revenue.
Analyze
Every denied claim is ingested, parsed, and categorized automatically. Denials 360 surfaces denial patterns by payer, CARC/RARC code, facility, provider, and service line — so your team sees exactly where revenue is leaking and why, in real time.
Triage
Not every denial deserves the same response. Denials 360 prioritizes claims by recovery probability, dollar value, and filing deadline — routing the highest-value opportunities to the front of the queue and flagging time-sensitive deadlines before they expire.
AI Actions
Based on the denial type, payer, and root cause, the platform triggers the right response automatically — whether that's a corrected resubmission, a documentation request, or escalation to the appeals workflow. Rules-governed tasks are handled without human intervention. Complex exceptions are routed to your team with full context attached.
Appeal
This is where our autonomous agents take over. When a denial requires a formal appeal, the system doesn't just flag it — it acts on it.
Smart Appeals Agent
An autonomous AI agent that generates payer-specific, regulation-compliant appeal letters using clinical documentation, payer policy rules, and denial history. It doesn't draft suggestions for your team to review and send — it executes the full appeals workflow independently: research, generate, and customize.
- Payer-specific language and formatting
- Tracks submission status and payer response
Payer Policy Copilot
The intelligence engine behind every appeal. Tracks payer-specific policy changes, CARC/RARC code patterns, timely filing windows, and appeal requirements in real time — ensuring every appeal is built on current rules, not outdated ones.
- Real-time payer policy change tracking
- CARC/RARC pattern analysis across your payer mix
- Filing deadline alerts before they expire
- Feeds intelligence directly into Smart Appeals Agent
The result is a system where denied claims move from identification to resolution with minimal manual touchpoints. Your experienced staff focus on complex exceptions that require human judgment. The AI handles the volume.
The question we hear most from healthcare leaders isn't "does it work?" — it's "can I trust it?" That's why we offer proof-of-concept pilots on your own data, transparent reporting on every decision the AI makes, and clear ROI tracking from day one. You see what the agent did, why it did it, and what the outcome was.
Agentic AI in denial management isn't the future. It's what forward-thinking health systems are deploying right now. The organizations that move first aren't just saving costs — they're building a competitive advantage in revenue recovery that compounds over time.
Start Your Pilot with DataRovers
See measurable denial management results on your own data within 1-3 months. No long-term commitment to get started — just real outcomes you can validate before scaling.
Free discovery call · No long-term commitment to start · Results in 1-3 months
Frequently Asked Questions
How long should a denial management vendor evaluation take?
A well-structured evaluation can be completed in 8-12 weeks. The typical 6+ month timeline usually results from scope creep, overly large evaluation committees, and sequential rather than parallel vendor assessments. Focus on a single use case (denial management), keep your team to 4-5 decision-makers, and run proof-of-concept pilots on your own data to compress the timeline without sacrificing due diligence.
Who should be involved in evaluating denial management software?
Keep the core evaluation team to 4-5 people: one representative each from finance (CFO or VP Finance), RCM operations (director level), IT/CIO, and clinical leadership. Designate a single decision-owner with final authority. Larger committees of 8-12 people add scheduling complexity and competing priorities without improving decision quality. KLAS recommends engaging cross-functional stakeholders early, but "early" doesn't mean "large."
What's the difference between AI-powered and rules-based denial management?
Rules-based systems apply static if-then logic to categorize denials (e.g., "if CARC = CO-4, route to coding"). AI-powered platforms use pattern recognition across payer behavior, denial trends, and clinical documentation to identify root causes and adapt over time. Agentic AI goes further — it can execute tasks autonomously, like generating and submitting appeals, rather than just flagging issues for human review. McKinsey and Deloitte both recommend prioritizing vendors with agentic AI capabilities for back-end RCM tasks.
Should we run a pilot before signing a contract?
Yes — a 30-60 day proof-of-concept on your own data is the single most important step in the evaluation process. Ask your top 2 vendors to work on a specific denial category or payer with a defined subset of your denial volume. Real results on your data beat vendor slide decks every time. McKinsey recommends evaluating pilots on three dimensions: staff/patient experience improvement, projected long-term financial impact, and near-term operational benefit.
What metrics should we use to evaluate denial management vendors?
Focus on 5-7 outcome-based metrics rather than feature checklists: denial rate reduction, appeal success rate, time-to-resolution, cost-to-collect impact, clean claim rate, integration timeline, and ROI payback period. Define these metrics before talking to vendors, and score every vendor against the same criteria. Black Book Research's 18 KPIs framework is a useful starting point, but 50-feature comparison spreadsheets don't predict real-world performance.
How do we build trust in AI-powered denial management?
Start with a contained pilot on a single denial category or payer — don't roll out organization-wide on day one. Require transparency in how the AI makes decisions; the vendor should be able to explain why it categorized a denial and what data it used. Keep humans in the loop for complex exceptions, and measure outcomes against your own baseline (not industry benchmarks). If the technology works, you'll see it in your denial rates and appeal success rates within 60-90 days.